CGT

1,163개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,163 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleMing YangPhase 1

IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody (IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody)

Recurrent Malignant Glioma · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleYake Biotechnology Ltd.Phase 1

IL3 CAR T-cells (IL3 CAR T-cells)

Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleBeijing Immunochina Medical Sci…Phase 1

IM21 CAR-T cells (IM21 CAR-T cells)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleHunan Zhaotai Yongren Medical I…Phase 2

ITNK cell therapy (ITNK cell therapy)

Anti-cancer Cell Immunotherapy; T Cell and NK Cell · Anti-cancer Cell Immunotherapy

#Anti-cancerCellImmunotherapy#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleLiping DouPhase 1

In vivo BCMA/GPRC5D Tandem Dual CAR-T cell (In vivo BCMA/GPRC5D Tandem Dual CAR-T cell)

Plasma Cell Neoplasms · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20 (Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20)

CD19 Negative B-cell Malignancies · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleDonghua ZhangPreclinical

Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies (Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies)

Relapsed/Refractory B-cell Malignancies · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMemorial Sloan Kettering Cancer…Phase 1

Infusion of MCARH109 T cells (Infusion of MCARH109 T cells)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleWenbin QianPhase 2

Interleukin-7 and Chemokine (C-C Motif, Interleukin-7 and Chemokine, Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells)

B Cell Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleT-MAXIMUM Pharmaceutical IncPhase 2

Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3 (Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3)

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype · Glioblastoma IDH (Isocitrate Dehydrogena

#GlioblastomaIDHIsocitrateDehydro#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 2

Investigational CAR-T (Investigational CAR-T)

Malignancy; Cancer · Malignancy

#Malignancy#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

Invivo CAR-T (Invivo CAR-T)

B-Acute Lymphoblastic Leukemia; B Cell Non-Hodgkin's Lymphoma · B-Acute Lymphoblastic Leukemia

#B-AcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleJuno Therapeutics, a Subsidiary…Phase 2

CD19-targeted CAR T cells (JCAR015, JCAR015 (CD19-targeted CAR T cells))

Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleJuno Therapeutics, a Subsidiary…Phase 1

JCAR017 (JCAR017, JCAR017 (lisocabtagene maraleucel) single-dose schedule, lisocabtagene maraleucel)

Non-Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleShanghai Ming Ju Biotechnology …Phase 1

CD19-targeted Chimeric Antigen Receptor Cells (JWCAR029, JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells))

Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 1

JWCAR129 (JWCAR129)

Safety and Efficacy · Safety and Efficacy

#SafetyandEfficacy#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleShanghai JW Therapeutics Co., L…Phase 1

JWCAR239 (JWCAR239)

B-Cell Non-Hodgkin Lymphoma; Large B Cell Diffuse Lymphoma · B-Cell Non-Hodgkin Lymphoma

#B-CellNon-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleWest China HospitalPhase 1

JWK010 gene therapy (JWK010 gene therapy)

Oculocutaneous Albinism (OCA) · Oculocutaneous Albinism (OCA)

#OculocutaneousAlbinismOCA#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleRong TaoPhase 1

KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells） (KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）)

Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 1

KRAS-EphA-2-CAR-DC (KRAS-EphA-2-CAR-DC)

Solid Tumor, Adult; EphA2 Overexpression · Solid Tumor, Adult

#SolidTumorAdult#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting

45 / 59 pages

← PreviousNext →